GLP-1 Drugs and Adenosine Share Hidden Pathways That May Calm Epilepsy
A new review maps how GLP-1 drugs and adenosine signaling overlap in epilepsy, pointing to possible combination strategies for seizures and metabolic disease.
Summary
Epilepsy affects about 83 million people worldwide, and many also live with type 2 diabetes or obesity, which worsen long-term outcomes. GLP-1 receptor agonists, drugs best known for treating diabetes and weight, are now being explored for brain disorders including epilepsy. This review argues that GLP-1 drugs and adenosine, a molecule that naturally dampens seizures and regulates metabolism, work through overlapping pathways. Both appear to reduce brain inflammation, scar-like astrocyte activation, and activity of the growth-signaling protein mTOR. Both may also rebalance brain excitation and inhibition by lowering glutamate signaling and boosting GABA signaling. In the body, the two systems intersect through the enzymes adenosine deaminase and DPP-4, fat metabolism, and insulin-producing beta cell health. The authors suggest these overlaps could support combination therapies and deserve further study, particularly for people with epilepsy and metabolic disease.
Detailed Summary
Epilepsy affects roughly 83 million people worldwide, and type 2 diabetes and obesity are common companions that shape quality of life and mortality. This overlap makes treatments that address both brain excitability and metabolic health especially attractive.
This review examines two systems that rarely appear together: GLP-1 receptor agonists, widely used for diabetes and obesity and increasingly studied in neurological disease, and adenosine, a metabolite that acts as the brain's natural anticonvulsant and also regulates metabolism. The authors ask whether the antiepileptic effects of GLP-1 drugs might partly run through adenosine-related mechanisms.
The abstract describes several shared actions. In the brain, both GLP-1 drugs and adenosine signaling reduce astrogliosis, neuroinflammation, and mTOR activity. Both help restore the balance between excitation and inhibition by suppressing glutamatergic signaling and strengthening GABAergic signaling. In peripheral organs, the pathways meet at adenosine deaminase and dipeptidylpeptidase-4 (DPP-4) interactions, lipid metabolism, and pancreatic beta cell homeostasis.
The implications are largely conceptual. If the mechanisms truly converge, combining GLP-1 drugs with adenosine-augmenting approaches could be synergistic, and adenosine biology could help explain why GLP-1 drugs seem to affect seizures. The authors also point to possible bidirectional relationships, in which metabolic state influences adenosine signaling and vice versa. Because inflammation, mTOR signaling, and metabolic dysfunction are also central to brain aging, the themes extend beyond epilepsy.
Several caveats apply. This is a narrative review, so it synthesizes existing work rather than testing a hypothesis directly, and much of the supporting evidence is likely preclinical. No clinical recommendations are made, and the convergence remains a hypothesis requiring experimental confirmation. One author discloses a financial interest in a company, PrevEp Inc. This summary is based on the abstract only.
Key Findings
- GLP-1 receptor agonists and adenosine signaling both reduce astrogliosis, neuroinflammation, and mTOR activity in epilepsy models.
- Both systems may restore excitation-inhibition balance by suppressing glutamate and upregulating GABA pathways.
- Peripheral overlap includes adenosine deaminase and DPP-4 interactions, lipid metabolism, and pancreatic beta cell homeostasis.
- Type 2 diabetes and obesity are common in epilepsy and affect outcomes, supporting metabolically targeted treatments.
- Authors propose synergistic therapies and call for study of bidirectional GLP-1 and adenosine relationships.
Methodology
This is a narrative review synthesizing literature on GLP-1 receptor agonists and adenosine signaling in epilepsy and metabolic disease. The abstract does not describe a systematic search method or evidence grading.
Study Limitations
This summary is based on the abstract only, as the full text is not open access. The review is narrative, the convergence of mechanisms is hypothetical, and much of the evidence is likely preclinical. One author discloses a financial interest in PrevEp Inc.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
